Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keverprazan-amoxicillin dual therapy in treatment-naive Helicobacter pylori infection
ChiCTR2600135430Phase 4Not yet recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of keverprazan, amoxicillin, vonoprazan and rabeprazole in Helicobacter pylori infection (4 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Eradication rate. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
keverprazanamoxicillinvonoprazanrabeprazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2600135430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135430.